Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 18 03:50PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.44 Insider Own15.72% Shs Outstand44.12M Perf Week-5.17%
Market Cap113.39M Forward P/E- EPS next Y-0.62 Insider Trans0.00% Shs Float37.18M Perf Month2.39%
Income-19.27M PEG- EPS next Q- Inst Own12.15% Short Float0.05% Perf Quarter1.58%
Sales18.13M P/S6.25 EPS this Y-104.76% Inst Trans-20.50% Short Ratio0.59 Perf Half Y-35.75%
Book/sh1.60 P/B1.61 EPS next Y12.79% ROA-14.37% Short Interest0.02M Perf Year63.69%
Cash/sh2.49 P/C1.03 EPS next 5Y- ROE-25.08% 52W Range1.10 - 4.38 Perf YTD33.06%
Dividend Est.- P/FCF- EPS past 5Y-5.97% ROI-22.86% 52W High-41.32% Beta0.63
Dividend TTM- Quick Ratio3.61 Sales past 5Y283.15% Gross Margin- 52W Low133.62% ATR (14)0.19
Dividend Ex-Date- Current Ratio3.61 EPS Y/Y TTM76.56% Oper. Margin-152.27% RSI (14)39.61 Volatility6.15% 7.12%
Employees174 Debt/Eq0.32 Sales Y/Y TTM91.01% Profit Margin-106.27% Recom1.00 Target Price10.60
Option/ShortNo / Yes LT Debt/Eq0.19 EPS Q/Q- Payout- Rel Volume0.45 Prev Close2.61
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 29 BMO Avg Volume33.13K Price2.57
SMA20-10.21% SMA50-5.16% SMA2005.14% Trades Volume14,500 Change-1.53%
Date Action Analyst Rating Change Price Target Change
Jun-25-21Initiated China Renaissance Buy $40.57
Mar-08-21Initiated Morgan Stanley Overweight $34
Mar-08-21Initiated Jefferies Buy $33
Mar-08-21Initiated Goldman Buy $29
Jul-12-24 07:00AM
May-22-24 04:45PM
Mar-29-24 09:00AM
Mar-07-24 04:01PM
Feb-27-24 08:00AM
06:00AM Loading…
Feb-09-24 06:00AM
Jan-17-24 07:00AM
Jan-16-24 05:01PM
Jan-04-24 05:00AM
Nov-03-23 12:00PM
Oct-30-23 09:40AM
Oct-13-23 09:40AM
Oct-12-23 08:00AM
Sep-27-23 09:40AM
Sep-07-23 10:45PM
09:40AM Loading…
Aug-31-23 07:32AM
May-25-23 09:40AM
May-04-23 09:00AM
Apr-28-23 07:00AM
Apr-18-23 09:17AM
Mar-31-23 09:40AM
Mar-28-23 04:30PM
Mar-14-23 06:00PM
Mar-05-23 07:39PM
Jan-09-23 07:00AM
Jan-05-23 04:01PM
Dec-16-22 06:30AM
Nov-21-22 04:05PM
09:05AM Loading…
Nov-10-22 09:05AM
Oct-11-22 04:03PM
Sep-10-22 04:13AM
Aug-30-22 05:25PM
Jun-29-22 04:05PM
May-26-22 09:30PM
May-12-22 07:00AM
May-02-22 06:06AM
Apr-08-22 01:09PM
Apr-03-22 02:34PM
Mar-31-22 08:30AM
Mar-17-22 10:42AM
Mar-16-22 10:00AM
Mar-08-22 09:21PM
Mar-02-22 08:22AM
Feb-08-22 07:00AM
Feb-02-22 04:05PM
Jan-27-22 07:00AM
Jan-19-22 07:00AM
Jan-13-22 04:00AM
Dec-22-21 04:05PM
Dec-13-21 10:23AM
Dec-06-21 01:49PM
Nov-30-21 04:01PM
Nov-29-21 04:05PM
Nov-22-21 05:05PM
Nov-09-21 04:05PM
Nov-04-21 09:24AM
Oct-27-21 08:52AM
Oct-21-21 08:00AM
Sep-17-21 12:22PM
Sep-02-21 07:45AM
Aug-26-21 07:45AM
Aug-19-21 07:37AM
Aug-12-21 07:45AM
Jul-22-21 07:45AM
Jul-12-21 10:15PM
Jul-09-21 10:47AM
Jul-07-21 07:45AM
Jun-16-21 04:49PM
May-25-21 04:05PM
May-19-21 05:05PM
Apr-13-21 07:45AM
Mar-31-21 07:45AM
Mar-29-21 07:45AM
Mar-16-21 08:05AM
Feb-11-21 10:08AM
Feb-09-21 05:18PM
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.